According tomedia BGR, the vaccine is the only drug that can stop us from contracting the new coronavirus. More than 100 vaccine candidates are currently under study, a small number of which have entered different stages of human trials. Although the signs are promising, we have not yet known whether these drugs are safe and effective. Once they are approved, it will take years for everyone in the world to be immunized. Thankfully, a new drug is currently being developed — a drug that can improve the condition of existing patients and even provide limited immunity to fight infection.
These drugs are antibody-based drugs that block the replication of SARS-CoV-2 virus in the body and improve the immune response of COVID-19 patients.
The first successful antibody therapy used plasma from patients recovered by COVID-19. Antibodies transplanted from people who have recovered to those struggling to get rid of infections have saved lives. But plasma does not meet demand, and antibody-based drugs appear. A series of reports detail ingress with such projects already under development in the United States, South Korea, China and elsewhere. Some will soon be in clinical trials, and the first drugs could be available later this year. Researchers have used a variety of antibodies that prevent the virus from replicating, including those that worked on the SARS virus nearly 20 years ago, and antibodies extracted from camels that are immune to COVID-19.
A new ABC News report details the work of a Bay Area team that has been working on an antibody therapy that could soon be used on a large scale. The lab has also been using SARS antibodies to fight the new virus. “Once we have this treatment in hand, if you have to go to the hospital, or if your loved ones have to go to the hospital, you can give them it instead of making them sicker and at risk of death, they’ll get better quickly and go home.” Dr. Jacob Glanville said. The doctor is best known for appearing in the “Pandemic” series, which is streaming on Netflix. He is also the CEO of Distributed Bio and its treatment company Centivax.
“We definitely need a vaccine, but it takes a long time, and you can’t vaccinate people who are already sick, because vaccines often take four, five, six weeks to take effect,” he added. But “as long as we have antibody therapy, we can end the crisis.” “
Stanford University and two other independent laboratories have confirmed that a variety of Centivax SARS antibodies can also neutralise SARS-CoV-2. This means that the drug can prevent the new coronavirus from binding to human cells and infecting human cells. Centivax hopes to enter clinical trials in August, with possible treatments likely to be released in September and awaiting regulatory approval.